本帖最后由 老马 于 2012-1-13 21:20 编辑 0 C5 \( k& V+ \# a( I
4 A; V$ K% x: m
爱必妥和阿瓦斯丁的比较
, U: c/ c* L0 P1 i# V
6 m, s$ _3 E- ]- p. ghttp://cancergrace.org/lung/2008/08/30/bms099-os-neg// B3 U6 s4 V% S! j8 H
' I, D- c- R, j* b' X
! [5 } ]3 g) N) V) m9 N: W( {6 ohttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 ^6 [$ X: e% n) n
==================================================
q/ V- Q' @2 h+ s; yOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)3 N+ n+ M& V9 a9 F
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 { ^4 u) v0 g3 tResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: |5 c* v1 j( U7 G
|
显身卡
# B' V: T% {0 p! a5 M
